Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Tirzepatide-Specific Safety Considerations GI symptoms are generally mild to moderate Risk of hypoglycemia when used with insulin or sulfonylureas Rare risk of pancreatitis (class effect) Possible thyroid C-cell effects (class warning) Heart rate increases have been documented, but are generally modest Retatrutide-Specific Safety Considerations Higher overall rate of side effects compared to tirzepatide in Phase 2 data More pronounced heart rate increase this is a dose-dependent effect directly related to glucagon receptor activation (glucagon is known to increase heart rate in pharmacological doses) At 12 mg doses, some participants experienced increases in heart rate of 46 bpm above baseline
Some patients may experience localized inflammatory responses, though true allergic reactions to tirzepatide are rare
Secure Messaging Direct access to your care team whenever you need it
A 2015 review in the Journal of Clinical Endocrinology confirming that GHRH analogs combined with ghrelin-pathway agonists produce a synergistic GH secretory response that exceeds additive effects when either compound is used alone provides the mechanistic basis for why combination therapy is the standard in supervised clinical settings
In general it is well tolerated , but it can cause nausea, diarrhoea or a characteristic body odour
- Administration: Can be injected subcutaneously or used in topical skincare formulations
